nhs_sign

NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza

pharmafile | October 1, 2018 | News story | Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma 

Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its once-daily single tablet regimen of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), meaning affected individuals will be able to access the drug through regular clinician prescriptions across England.

The combination will be made available to adult and adolescent patients aged 12 years and older who weigh at least 40kg, and is the only single tablet regimen available in this patient population. These patients will be able to access the drug when:

  • It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF fixed dose combination (FDC) utilised under the tenofovir-AF policy
  • It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF FDC, used outside the tenofovir-AF policy where there is a multidisciplinary team (MDT)-documented requirement for this regimen and it falls within regional prescribing guidelines

“We are delighted that NHSE has provided vital funding for this treatment option; enabling access for individuals who require a darunavir-based STR to effectively control their HIV, with the potential to support adherence to treatment,” says Jennifer Lee, Director of Health Economics, Market Access and Reimbursement (HEMAR) and Advocacy at Janssen. “This milestone reflects our efforts to help simplify the way in which HIV is treated, supporting people living with HIV to achieve an undetectable viral load while enjoying an improved quality of life. We are thankful for NHSE’s collaboration throughout this process.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

Five Facts about NHS and primary care

1 Primary care is the front door to the NHS, but it extends well beyond …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content